The test provides valuable information you can use to personalize a treatment plan specifically for each patient’s situation—including risk of distant recurrence, the benefit from chemotherapy and whether your patient can be treated effectively with hormonal therapy alone.), the St.
Gallen Consensus panel, the National Institute for Health Care Excellence (NICE), the European Society for Medical Oncology (ESMO) and the German Association of Gynecological Oncology (AGO).—for patients who are newly diagnosed with early-stage invasive breast cancer.
But, it is important to remember that no two breast cancer patients—or their tumors—are alike.
The Oncotype DX Breast Recurrence Score test provides a genomic-based, comprehensive, individualized risk assessment for early-stage invasive breast cancer in adjuvant and neoadjuvant settings.
Although carefully collected, accuracy cannot be guaranteed. Differing provisions from the publisher's actual policy or licence agreement may be applicable.
The approach taken by the authors allowed them to avoid one of the major pitfalls of developmental studies, which is that they often provide highly biased estimates of accuracy.
The fundamental principle is that the same data should not be used for developing a predictive classifier and for evaluating the accuracy of that classifier.
Eligible patients are diagnosed with early stage, ER , HER2- breast cancer with either node-negative or node-positive disease.
The test uses RT-PCR to measure the expression of 21 genes: 16 cancer-related genes and five reference genes - in a tumor sample after it has been removed by surgery or biopsy.